journal1 ›› 2019, Vol. 27 ›› Issue (1): 56-58.DOI: 10.11852/zgetbjzz2018-1095

Special Issue: 孤独症谱系障碍

Previous Articles     Next Articles

Advance on insulin-like growth factor-1 in autism spectrum disorders

HONG Xiao-wen, CHEN Yan-hui   

  1. Department of Pediatrics,Fujian Medical University Union Hospital,Fuzhou,Fujian 350001,China
  • Received:2018-08-12 Online:2019-01-10 Published:2019-01-10
  • Contact: CHEN Yan-hui,


洪晓文 综述, 陈燕惠 审校   

  1. 福建医科大学附属协和医院儿科,福建 福州 350001
  • 通讯作者: 陈燕惠,
  • 作者简介:洪晓文(1991-),女,福建人,硕士研究生,主要研究方向为小儿神经疾病及发育行为。

Abstract: The diagnosis of autism spectrum disorder (ASD) is mainly dependent on behavioral symptoms,and most children could not receive accurate diagnosis until 4 years old when the impairment of social interaction presents typically and the best period of intervention has been missed. It is worth noting that scientists have made a lot of theoretical and practical research on the pathological mechanism and drug target of ASD. And more and more studies have shown that the biomarker,insulin-like growth factor-1 (IGF-1),plays an important role in the development and progression in ASD. This review will summarize the role of IGF-1 in ASD in order to elucidate that IGF-1 is expected to be a biomarker of early diagnosis and early prevention of ASD,and to explore the application of IGF-1.

Key words: autism spectrum disorder, insulin-like growth factor-1, SHANK3 gene, Engrailed2 gene, MECP2 protein

摘要: 孤独症谱系障碍(ASD)确诊主要采用现有行为学症状诊断方法,大多数ASD儿童在到了4岁左右才得到准确诊断,而此时患儿的社交障碍已经十分明显,错失了干预治疗的最佳时期。值得注意的是,国内外学者对ASD的病理机制和药物靶标进行了大量研究,越来越多结果表明胰岛素样生长因子-1(IGF-1)在ASD的发生发展中占据重要地位。本文针对IGF-1在ASD中的作用进行综述,目的是为阐明IGF-1有望成为ASD早期诊断、早期治疗的生物标志物及探讨IGF-1在ASD中的应用前景。

关键词: 孤独症谱系障碍, 胰岛素样生长因子-1, SHANK3基因, Engrailed2基因, MECP2蛋白

CLC Number: